Tirzepatide with levocarnitine Tirzepatide with levocarnitine combines the weight loss medication with an amino acid involved in fat metabolism
Several studies have shown that Mounjaro is more effective than Ozempic for blood sugar control and weight loss
Dosage decisions and adjustments are individualized and guided by clinical evidence
Review Nexus lab verification

| Category | Zepbound | Mounjaro | |-----------------------------------|------------------------------------------------|------------------------------------------------| | FDA Approval Indication | Obesity and overweight management (with comorbidities) | Type 2 diabetes management | | Year of FDA Approval | 2023 | 2022 | | Active Ingredient | Tirzepatide | Tirzepatide | | Dose Range | 2.5 mg to 15 mg once weekly | 2.5 mg to 15 mg once weekly | | Primary Clinical Purpose | Weight loss | Blood sugar control | | GLP-1/GIP Activity | Dual agonist (GLP-1 + GIP) | Dual agonist (GLP-1 + GIP) | | Average Weight Loss (in trials) | Up to 22.5% of body weight in SURMOUNT-1 study | Up to 15% of body weight in SURPASS studies | | Insulin Sensitivity Impact | Improves insulin sensitivity in patients with obesity | Improves insulin sensitivity in type 2 diabetes patients | | Delivery Method | Single-use auto-injector pen, subcutaneous injection | Single-use auto-injector pen, subcutaneous injection | | Dosing Frequency | Once weekly | Once weekly | | Manufacturer | Eli Lilly | Eli Lilly | | Common Side Effects | Nausea, vomiting, diarrhea, constipation, decreased appetite | Nausea, vomiting, diarrhea, constipation, decreased appetite | | Insurance Coverage | Variable
%20causes%20abdominal%20pain%3F)